

**Quarterly Project Update Report: PharMHold Inc. Drug Manufacturing Quality System**

---

### Executive Summary

PharMHold Inc.'s Drug Manufacturing Quality System project is progressing steadily through the Monitoring & Evaluation phase, which typically follows Initial Setup and Testing phases. As of Q3 2023, approximately 60% of the project milestones have been achieved. Key progress points include the completion of test batch runs, the implementation of new quality assurance tools, and stakeholder reviews. The project is on track to meet its overall timeline but with some minor delays in finalizing documentation.

### Key Milestones Achieved

- **Test Batch Runs:** 75% of scheduled test batches have been completed.
- **Quality Assurance Tools:** 80% of new software tools have been implemented, enhancing data tracking and analysis capabilities.
- **Stakeholder Reviews:** All internal reviews have been finalized, with stakeholder feedback incorporated.

### Current Risks and Blockers

- **Staff Turnover:** A challenge has arisen due to departing employees. PharMHold has addressed this by hiring temporary staff during peak work periods and offering severance packages to departing employees.
- **Third-Party Vendors:** Delays in third-party vendor deliveries are causing slight delays, but PharMHold is actively negotiating better contracts to mitigate this risk.

### Next Quarter Objectives

The next quarter will focus on finalizing remaining test batches (25% more than planned), completing documentation, and preparing for full-scale operations. The goal is to achieve 100% completion of these tasks by the end of Q4.

### Resource and Budget Overview

- **Budget Utilization:** Approximately 70% of the allocated budget has been utilized, with some unused funds due to project delays.
- **Staffing:** Additional staff have been hired during the quarter to support testing activities.
- **Vendor Collaboration:** PharMHold is nearing completion with third-party vendor contracts, ensuring timely deliveries.

This report reflects PharMHold's commitment to managing risks and meeting project objectives efficiently.